GENE SILENCING AT THE DNA LEVEL Trademark
Trademark Overview
On Friday, June 5, 2020, a trademark application was filed for GENE SILENCING AT THE DNA LEVEL with the United States Patent and Trademark Office. The USPTO has given the GENE SILENCING AT THE DNA LEVEL trademark a serial number of 88949940. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Monday, October 18, 2021. This trademark is owned by Oncogenuity Inc.. The GENE SILENCING AT THE DNA LEVEL trademark is filed in the Computer & Software Services & Scientific Services category with the following description:
Pharmaceutical product development services; Pharmaceutical product evaluation services; Pharmaceutical research and development; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development of pharmaceuticals for the treatment of cancer and oncological conditions; Research and development of vaccines and medicines; Technical research in the field of pharmaceutical studies; Development of platform technology, namely, developing a cancer immunotherapy computer platform for manufacturing therapeutics; Consulting services for others in the field of design, planning, and implementation of clinical trials; IT platform as Service (PaaS) featuring computer software platforms for cancer diagnosis and analysis of cancer symptoms and cancer treatment, in the medical field; electronic data storage; Providing a bioinformatics platform as a service (PAAS) featuring computer software platforms for sequence data analysis in the fi...
General Information
| Serial Number | 88949940 |
| Word Mark | GENE SILENCING AT THE DNA LEVEL |
| Filing Date | Friday, June 5, 2020 |
| Status | 602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE |
| Status Date | Monday, October 18, 2021 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Goods and Services | Pharmaceutical product development services; Pharmaceutical product evaluation services; Pharmaceutical research and development; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development of pharmaceuticals for the treatment of cancer and oncological conditions; Research and development of vaccines and medicines; Technical research in the field of pharmaceutical studies; Development of platform technology, namely, developing a cancer immunotherapy computer platform for manufacturing therapeutics; Consulting services for others in the field of design, planning, and implementation of clinical trials; IT platform as Service (PaaS) featuring computer software platforms for cancer diagnosis and analysis of cancer symptoms and cancer treatment, in the medical field; electronic data storage; Providing a bioinformatics platform as a service (PAAS) featuring computer software platforms for sequence data analysis in the field of manufacturing therapeutics; Medical and scientific research information in the field of cell therapy; Scientific research and analysis for medical purposes in the field of cancer, oncology and clinical trials |
Classification Information
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, June 26, 2020 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Oncogenuity Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | New York, NY 10014 |
Trademark Events
| Event Date | Event Description |
| Monday, October 18, 2021 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
| Monday, October 18, 2021 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| Monday, April 5, 2021 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Monday, April 5, 2021 | FINAL REFUSAL E-MAILED |
| Monday, April 5, 2021 | FINAL REFUSAL WRITTEN |
| Tuesday, March 16, 2021 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, March 15, 2021 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, March 15, 2021 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, September 16, 2020 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, September 16, 2020 | NON-FINAL ACTION E-MAILED |
| Wednesday, September 16, 2020 | NON-FINAL ACTION WRITTEN |
| Wednesday, September 9, 2020 | ASSIGNED TO EXAMINER |
| Friday, June 26, 2020 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Tuesday, June 9, 2020 | NEW APPLICATION ENTERED IN TRAM |
